72 related articles for article (PubMed ID: 31907980)
21. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract][Full Text] [Related]
22. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
[TBL] [Abstract][Full Text] [Related]
23. MEK1 and MEK2 isoforms regulate distinct functions in pancreatic cancer cells.
Zhou L; Tan X; Kamohara H; Wang W; Wang B; Liu J; Egami H; Baba H; Dai X
Oncol Rep; 2010 Jul; 24(1):251-5. PubMed ID: 20514469
[TBL] [Abstract][Full Text] [Related]
24. Decreased c-Myc mRNA Stability via the MicroRNA 141-3p/AUF1 Axis Is Crucial for p63α Inhibition of Cyclin D1 Gene Transcription and Bladder Cancer Cell Tumorigenicity.
Li X; Tian Z; Jin H; Xu J; Hua X; Yan H; Liufu H; Wang J; Li J; Zhu J; Huang H; Huang C
Mol Cell Biol; 2018 Nov; 38(21):. PubMed ID: 30104251
[TBL] [Abstract][Full Text] [Related]
25. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
[TBL] [Abstract][Full Text] [Related]
26. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
[TBL] [Abstract][Full Text] [Related]
27. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.
Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697
[TBL] [Abstract][Full Text] [Related]
28. A full-length 3D structure for MAPK/ERK kinase 2 (MEK2).
Liang H; Liu T; Chen F; Liu Z; Liu S
Sci China Life Sci; 2011 Apr; 54(4):336-41. PubMed ID: 21509657
[TBL] [Abstract][Full Text] [Related]
29. Human GCIP interacts with CT847, a novel Chlamydia trachomatis type III secretion substrate, and is degraded in a tissue-culture infection model.
Chellas-Géry B; Linton CN; Fields KA
Cell Microbiol; 2007 Oct; 9(10):2417-30. PubMed ID: 17532760
[TBL] [Abstract][Full Text] [Related]
30. GADD45α and γ interaction with CDK11p58 regulates SPDEF protein stability and SPDEF-mediated effects on cancer cell migration.
Tamura RE; Paccez JD; Duncan KC; Morale MG; Simabuco FM; Dillon S; Correa RG; Gu X; Libermann TA; Zerbini LF
Oncotarget; 2016 Mar; 7(12):13865-79. PubMed ID: 26885618
[TBL] [Abstract][Full Text] [Related]
31. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells.
Appleman LJ; van Puijenbroek AA; Shu KM; Nadler LM; Boussiotis VA
J Immunol; 2002 Mar; 168(6):2729-36. PubMed ID: 11884439
[TBL] [Abstract][Full Text] [Related]
32. MEK2 Negatively Regulates Lipopolysaccharide-Mediated IL-1β Production through HIF-1α Expression.
Talwar H; Bouhamdan M; Bauerfeld C; Talreja J; Aoidi R; Houde N; Charron J; Samavati L
J Immunol; 2019 Mar; 202(6):1815-1825. PubMed ID: 30710049
[TBL] [Abstract][Full Text] [Related]
33. RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
Wang S; Wang X; Gao Y; Peng Y; Dong N; Xie Q; Zhang X; Wu Y; Li M; Li JL
J Pathol; 2019 Jun; 248(2):204-216. PubMed ID: 30714150
[TBL] [Abstract][Full Text] [Related]
34. SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling.
Lin YC; Lu LT; Chen HY; Duan X; Lin X; Feng XH; Tang MJ; Chen RH
Cancer Res; 2014 Dec; 74(23):6935-46. PubMed ID: 25293974
[TBL] [Abstract][Full Text] [Related]
35. MEK1 and MEK2 differentially control the duration and amplitude of the ERK cascade response.
Kocieniewski P; Lipniacki T
Phys Biol; 2013 Jun; 10(3):035006. PubMed ID: 23735655
[TBL] [Abstract][Full Text] [Related]
36. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
37. SUMO-specific protease 2-mediated deSUMOylation is required for NDRG2 stabilization in gastric cancer cells.
Hu XY; Liu Z; Zhang KL; Feng J; Liu XF; Wang LY; Wang ZW
Cancer Biomark; 2017 Dec; 21(1):195-201. PubMed ID: 29060933
[TBL] [Abstract][Full Text] [Related]
38. Elevated O-GlcNAcylation promotes gastric cancer cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling.
Jiang M; Qiu Z; Zhang S; Fan X; Cai X; Xu B; Li X; Zhou J; Zhang X; Chu Y; Wang W; Liang J; Horvath T; Yang X; Wu K; Nie Y; Fan D
Oncotarget; 2016 Sep; 7(38):61390-61402. PubMed ID: 27542217
[TBL] [Abstract][Full Text] [Related]
39. Interaction of tRNA with MEK2 in pancreatic cancer cells.
Wang X; Chow CR; Ebine K; Lee J; Rosner MR; Pan T; Munshi HG
Sci Rep; 2016 Jun; 6():28260. PubMed ID: 27301426
[TBL] [Abstract][Full Text] [Related]
40. PAX3 is a novel tumor suppressor by regulating the activities of major signaling pathways and transcription factor FOXO3a in thyroid cancer.
Liu W; Sui F; Liu J; Wang M; Tian S; Ji M; Shi B; Hou P
Oncotarget; 2016 Aug; 7(34):54744-54757. PubMed ID: 27458157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
